Hormonal
Insulin resistance (IR) is the primary mechanistic link connecting Metabolic Syndrome (MetS) to increased risk of Alzheimer's Disease (AD) and cognitive impairment, driven by impaired PI3K-Akt signaling, increased amyloid-beta (Aβ) production, and tau hyperphosphorylation.
Maintain metabolic health to protect your brain. If you have metabolic syndrome, obesity, or type 2 diabetes, your risk for cognitive decline is significantly higher due to insulin resistance. Prioritize interventions that improve insulin sensitivity (like exercise and diet) as they may directly protect against Alzheimer's pathology by preserving brain insulin signaling.
Insulin resistance (IR) is at the core of MetS and likely represent the key link between MetS and AD... In this review, we will discuss MetS as a risk factor for AD, focusing on IR and the recent progress and future directions of insulin-based therapies.
Why this rating
Based on a comprehensive review of multiple longitudinal human studies, animal models, and mechanistic pathways, though it is a review paper rather than a single RCT.
Source
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome
Bhumsoo Kim et al. · Experimental & Molecular Medicine · 2015
DOI 10.1038/emm.2015.3
More from this paper
- Intranasal insulin administration improves memory and cognitive function in early Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients, particularly those who are ApoE-ε4 negative.Moderate
- GLP-1 analogues (e.g., liraglutide, exenatide) show promise in animal models for reducing amyloid plaques, tau phosphorylation, and improving cognition, but human clinical trials have shown mixed or disappointing results so far.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →